Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Stanford University
This study is the first to assess the perioperative time course of systemic inflammation and immunity in colon cancer patients and evaluate the effect of anti-inflammatory treatment with celecoxib on this response. In addition, evaluation of the effect of short-term preoperative administration of celecoxib on tumor immunogenicity will help us to understand how tumor-enhancing inflammation and anti-tumor immunity can be differentially affected by COX-2 inhibitors. The knowledge gained as a result of this research will help us to set up the infrastructure for a method to monitor the immunoinflammatory status of colon cancer patients with a longer term goal of designing interventions to suppress tumor-enhancing inflammation and vitalize anti-tumor immunity in the perioperative period. The long-term objective is to use these novel tools in order to improve cancer-specific survival in patients with colon cancer after primary tumor resection.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\- Colon cancer patients with no evidence of metastasis in distant organs (i.e., TNM stage I-III), who are
between 18 and 75 years old,
have a body mass index (BMI) between 18 and 35 kg/m\^2,
and are eligible for laparoscopically-assisted colectomy for primary tumor resection.
Patients must have the ability to understand and the willingness to sign a written informed consent document.
You may not be if
\- A history of allergic-type reactions to celecoxib or sulphonamides,
a history of asthma, skin reactions or other allergic reactions to aspirin or other NSAIDs,
a history of thromboembolic event (cerebrovascular accident, transient ischemic attack,
unstable angina, myocardial infarction, deep vein thrombosis, or pulmonary embolism),
renal insufficiency (defined by a serum creatinine level \> 1.5 mg/dL or blood urea nitrogen level \> 22 mg/dL),
active gastrointestinal bleeding in the 60 days before surgery,
alcohol or drug abuse, and
previous chemotherapy or abdominal/pelvic radiation therapy.
